Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer and autoimmune diseases. We utilize T cells from donors with healthy immune function, with the goal to specifically recognize and target cancerous or diseased cells in patients without affecting normal cells. Our investigational off-the-shelf T cells are intended for rapid delivery from inventory to patients.
Transform the lives of patients with serious diseases through pioneering science, teamwork, and a commitment to excellence
Our unique platform is to create off-the-shelf, allogeneic T-cell libraries that can be used to select the appropriate cells for a patient's unique immune profile.View Technology
Our robust pipeline features multiple T-cell immunotherapies in clinical and pre-clinical development
T-cell immunotherapy for EBV-associated ultra-rare diseases
FDA breakthrough designation & EMA PRIME for EBV+ PTLD
EBV CD19 CAR T
Next-generation off-the-shelf, allogeneic CD19-1XX CAR+ EBV T-cell immunotherapy containing a modified CD3ζ signaling domain, 1XX